Get started

Financials · PRLD

Prelude Therapeutics Incorporated (PRLD) financials

For the twelve months ended Jun 30, 2026, Prelude Therapeutics Incorporated reported $22.42M of revenue and -$60.49M of net income.

Revenue, TTM
$22.42M
Revenue growth, YoY
+220.3%
Net income, TTM
-$60.49M
Net margin
-269.7%
Free cash flow, TTM
-$33.26M
EPS, diluted, TTM
-$0.73
Cash
$26.33M
P/S
13.38
Market cap
$300.1M
Annual revenue$12.14M
FY2024FY2025
Annual net income-$99.50M
FY2019FY2025
Annual free cash flow-$56.37M
FY2019FY2025

PRLD revenue and earnings growth

PRLD revenueQ2 2026$5.70M

QoQ
+24.5%
FY YoY
+73.4%

PRLD revenue was $5.70M in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier and up 24.5% from the prior quarter. For the full fiscal 2025 it was $12.14M, up 73.4% from fiscal 2024.

PRLD net incomeQ2 2026-$13.92M

PRLD net income was -$13.92M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$31.23M a year earlier. For the full fiscal 2025 it was -$99.50M, compared with -$127.17M in fiscal 2024.

PRLD EPSQ2 2026-$0.14

PRLD diluted EPS was -$0.14 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.41 a year earlier. For the full fiscal 2025 it was -$1.29, compared with -$1.68 in fiscal 2024.

PRLD free cash flowQ2 2026-$15.57M

PRLD free cash flow was -$15.57M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$26.09M a year earlier. For the full fiscal 2025 it was -$56.37M, compared with -$103.65M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue$12.14M$7.00M-----
Research and development$94.30M$118.00M$103.39M$92.89M$86.78M$48.18M$24.28M
Selling, general and admin$22.41M$28.72M$28.88M$30.65M$26.96M$10.59M$3.83M
Operating income-$104.57M-$139.71M-$132.28M-$123.54M-$113.73M-$58.76M-$28.11M
Income tax$0$0-----
Net income-$99.50M-$127.17M-$121.83M-$115.44M-$111.69M-$56.93M-$27.57M
EPS, basic-$1.29-$1.68-$2.02-$2.44-$2.43-$4.56-$16.52
EPS, diluted-$1.29-$1.68-$2.02-$2.44-$2.43-$4.56-$16.52
Diluted shares77.0M75.8M60.4M47.4M46.0M12.5M1.7M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Cash and equivalents$35.26M$12.47M$25.29M$30.61M$31.83M$218.31M$18.88M
Short-term investments$67.96M$121.14M$207.64M$171.12M$259.40M--
Current assets$105.69M$135.90M$235.59M$204.38M$295.12M$220.81M$20.22M
Total assets$141.31M$175.51M$277.67M$220.50M$305.10M$223.59M$21.87M
Current liabilities$52.99M$25.64M$21.83M$21.70M$19.20M$11.38M$4.83M
Total liabilities$72.68M$44.06M$40.58M$25.06M$19.20M$11.41M$4.84M
Shareholders' equity$68.64M$131.46M$237.09M$195.44M$285.90M$212.18M-$49.41M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Operating cash flow-$56.30M-$102.89M-$107.06M-$83.73M-$83.53M-$46.18M-$25.66M
Capital expenditures$67.0K$764.0K$3.51M$3.02M$2.32M$621.0K$780.0K
Free cash flow-$56.37M-$103.65M-$110.58M-$86.75M-$85.85M-$46.80M-$26.45M
Investing cash flow$53.46M$90.19M-$34.65M$81.69M-$263.80M-$621.0K-$780.0K
Financing cash flow$24.82M-$120.0K$136.40M$815.0K$164.90M$246.23M$29.73M
Stock-based compensation$11.91M$21.34M$25.62M$25.14M$20.93M$5.58M$846.0K
Depreciation and amortization$1.71M$1.77M$1.17M$1.32M$915.0K$542.0K$382.0K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
Revenue growth, YoY73.4%------
Operating margin-861.3%-1995.9%-----
Net margin-819.6%-1816.8%-----
Free cash flow margin-464.3%-1480.7%-----
Return on equity-145.0%-96.7%-51.4%-59.1%-39.1%-26.8%-
Return on assets-70.4%-72.5%-43.9%-52.4%-36.6%-25.5%-126.1%
Current ratio1.995.3010.799.4215.3719.414.18

Source: XBRL data Prelude Therapeutics Incorporated files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

PRLD peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
PRLD$22.42M+220.3%-$60.49M-269.7%$300.1M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

PRLD FAQ

8 questions
  • What is PRLD revenue?
    Prelude Therapeutics Incorporated (PRLD) reported $22.42M of revenue for the twelve months ended Jun 30, 2026. That is up 220.3% from the year before. Revenue for fiscal 2025 was $12.14M.
  • Is PRLD profitable?
    No. Prelude Therapeutics Incorporated reported a net loss of $60.49M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does PRLD have?
    Prelude Therapeutics Incorporated reported $26.33M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is PRLD revenue growing?
    Prelude Therapeutics Incorporated's revenue changed +73.4% in fiscal 2025, to $12.14M.
  • What is PRLD free cash flow?
    Prelude Therapeutics Incorporated generated -$33.26M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$33.26M less capital expenditures.
  • What is PRLD earnings per share?
    Diluted earnings per share were -$0.73 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did PRLD last report financial results?
    The latest statements here come from Prelude Therapeutics Incorporated's 10-Q filed on Aug 11, 2026, covering the period ended Jun 30, 2026.
  • Where does this PRLD financial data come from?
    Quantisnow builds these statements from the structured XBRL data Prelude Therapeutics Incorporated files with the SEC. It is provided for information only and is not investment advice.